Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects
treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the
percent of subjects who achieve a clinically meaningful symptom improvement (ie, total
symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is
also designed to demonstrate that these responses are durable with continued treatment.